Akero’s NASH candidate reduces liver fat in patients taking a GLP-1
Akero Therapeutics said its NASH drug reduced liver fat in patients who were also taking a GLP-1 agonist.
The NASH-focused biotech on Monday released topline data from a Phase IIb trial for 32 patients with type 2 diabetes and F1-F3 liver fibrosis due to NASH who participated in the SYMMETRY study for 12 weeks. Liver fibrosis is scored based on how progressive it is; F1 fibrosis is indicative of minimal scarring, while F3 is typically seen as severe.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.